RG
GALT icon

Rathbones Group’s Galectin Therapeutics GALT Stock Holding History

Rathbones Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,400
Closed -$78K – 310
2018
Q1 		$78K Hold
16,400
– – ﹤0.01% 301
2017
Q4 		$55K Hold
16,400
– – ﹤0.01% 309
2017
Q3 		$35K Hold
16,400
– – ﹤0.01% 307
2017
Q2 		$40K Hold
16,400
– – ﹤0.01% 307
2017
Q1 		$38K Hold
16,400
– – ﹤0.01% 317
2016
Q4 		$16K Hold
16,400
– – ﹤0.01% 311
2016
Q3 		$19K Hold
16,400
– – ﹤0.01% 309
2016
Q2 		$24K Hold
16,400
– – ﹤0.01% 303
2016
Q1 		$23K Hold
16,400
– – ﹤0.01% 300
2015
Q4 		$21K Hold
16,400
– – ﹤0.01% 293
2015
Q3 		$38K Hold
16,400
– – ﹤0.01% 299
2015
Q2 		$45K Hold
16,400
– – ﹤0.01% 315
2015
Q1 		$55K Hold
16,400
– – ﹤0.01% 319
2014
Q4 		$57K Hold
16,400
– – ﹤0.01% 317
2014
Q3 		$82K Buy
+16,400
New +$128K 0.01% 294

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Rathbones Group's GALT Position: Q2 2018 in Review

Rathbones Group sold out of Galectin Therapeutics (GALT) in Q2 2018, closing a stake of 16,400 shares — an estimated $78K sold.

Rathbones Group first reported a position in GALT in Q3 2014 and held it in 15 quarters. The position peaked at $82K in Q3 2014. 69 funds tracked by Wall St. Rank hold GALT as of Q2 2018.

  • Rathbones Group reported no remaining Galectin Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Rathbones Group sold 16,400 Galectin Therapeutics shares in Q2 2018, an estimated $78K.
  • Rathbones Group first reported a position in Galectin Therapeutics in Q3 2014 and held it in 15 quarters.
  • Rathbones Group's Galectin Therapeutics position peaked at $82K in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2018.

Based on Rathbones Group's 13F filing for Q2 2018, filed 16 Jul 2018.